Chemours Co(CC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,969 of 2,960 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in CC
Events flagged as statistical outliers against CC's own multi-year baseline — not fixed dollar thresholds.
- Insider cluster2026-08-12
7 insiders bought $488,619 of CC in 30 days — 14.0σ above this company's 2-year norm
View source filing → - Insider cluster2026-08-07
5 insiders bought $408,068 of CC in 30 days — 10.0σ above this company's 2-year norm
View source filing →
CC Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Chemours Co (CC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CC at 43.4/100 on a 32-signal composite quality model, placing it at rank #1,969 of 2,960 stocks — the bottom half of the AI-ranked universe. CC scores in the top quartile across revenue scale (79.9). Areas of concern include balance sheet strength (23.5) and revenue growth (24.7), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Chemours Co reports quarterly revenue of $1.6B, net income of $-274.0M, an operating margin of -0.1%. Top institutional holders of CC by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CC trades on the NYSE exchange and files with the SEC under CIK 1627223. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Chemours Co directly from SEC EDGAR. Chemours Co's 13F Pro composite quality score has ranged between 36 and 71 since 2021, currently 43.4 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
What's Driving CC's Business? Latest 10-Q Breakdown
AI-extracted from Chemours Co's 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Chemours reported Q2 revenue of $1,591M, down 1% YoY, with net loss of $274M driven by $273M tax provision from valuation allowances and $552M accrued PFAS litigation liabilities.
Biggest Revenue Drivers
Titanium dioxide sales flat at $639M; minerals & other at $22M.
Opteon refrigerants $337M (-10%), Freon $150M (+22%), foam/propellants $104M (+5%).
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q2 2026
$1.6B
Net Income
Q2 2026
$-274.0M
Free Cash Flow
Q2 2026
$114.0M
Operating Margin
Q2 2026
-0.1%
ROIC
Q2 2026
-0.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+0.4% YoYNet Income
-659.4% YoYEPS (Diluted)
-658.7% YoYTotal Assets
-1.7% YoYTotal Debt
+0.8% YoYOp. Cash Flow
+141.7% YoYFree Cash Flow
+105.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.81B +0.4% | $5.78B -4.9% | $6.08B -11.0% | $6.83B +7.7% | $6.34B +27.7% | $4.97B |
| Net Income | $-386.0M -659.4% | $69.0M +127.3% | $-253.0M -143.8% | $578.0M -4.9% | $608.0M +177.6% | $219.0M |
| EPS (Diluted) | $-2.57 -658.7% | $0.46 +127.1% | $-1.70 -146.6% | $3.65 +1.4% | $3.60 +172.7% | $1.32 |
| Total Assets | $7.38B -1.7% | $7.51B -9.0% | $8.25B +8.0% | $7.64B +1.2% | $7.55B +6.6% | $7.08B |
| Total Debt | $4.14B +0.8% | $4.11B +1.7% | $4.04B +11.2% | $3.63B -3.1% | $3.75B -6.9% | $4.03B |
| Operating Cash Flow | $264.0M +141.7% | $-633.0M -213.8% | $556.0M -26.4% | $755.0M -7.2% | $814.0M +0.9% | $807.0M |
| Free Cash Flow | $51.0M +105.1% | $-993.0M -633.9% | $186.0M -58.5% | $448.0M -16.6% | $537.0M -0.6% | $540.0M |
Get alerted when CC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Chemours Co including:
Top Institutional Holders of CC
BlackRock, Inc.
$477.8M23,283,074 shVANGUARD PORTFOLIO MANAGEMENT LLC
$216.9M10,568,867 shVANGUARD CAPITAL MANAGEMENT LLC
$139.2M6,784,588 shSTATE STREET CORP
$125.5M6,115,375 shAMERIPRISE FINANCIAL INC
$101.0M4,924,004 shAMERICAN CENTURY COMPANIES INC
$89.9M4,379,525 shJPMORGAN CHASE & CO
$85.2M4,199,395 shGEODE CAPITAL MANAGEMENT, LLC
$78.5M3,823,361 shCOOPER CREEK PARTNERS MANAGEMENT LLC
$76.0M3,701,248 shVOYA INVESTMENT MANAGEMENT LLC
$72.7M3,544,702 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $477.8M | 23,283,074 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $216.9M | 10,568,867 |
| VANGUARD CAPITAL MANAGEMENT LLC | $139.2M | 6,784,588 |
| STATE STREET CORP | $125.5M | 6,115,375 |
| AMERIPRISE FINANCIAL INC | $101.0M | 4,924,004 |
| AMERICAN CENTURY COMPANIES INC | $89.9M | 4,379,525 |
| JPMORGAN CHASE & CO | $85.2M | 4,199,395 |
| GEODE CAPITAL MANAGEMENT, LLC | $78.5M | 3,823,361 |
| COOPER CREEK PARTNERS MANAGEMENT LLC | $76.0M | 3,701,248 |
| VOYA INVESTMENT MANAGEMENT LLC | $72.7M | 3,544,702 |
Companies Similar to CC
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
OLIN Corp
Viatris Inc
Brookdale Senior Living Inc.
Organon & Co.
DENTSPLY SIRONA Inc.
Huntsman CORP
GE HealthCare Technologies Inc.
MOLINA HEALTHCARE, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CC on your watchlist
Track score changes the day Chemours Co files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CC a good stock to buy?
13F Pro's AI-powered analysis of Chemours Co (CC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CC are available on the CC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CC is classified as a mid company.
Which hedge funds own CC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Chemours Co's investment landscape.